View More Recent Stories
-
Scholar Rock Holding (SRRK) +33% today after Biohaven’s SMA study update miss
-
Scholar Rock (SRRK) PT Raised to $45 at Truist Securities on Biohaven's data miss
-
Scholar Rock (SRRK) PT Raised to $39 at BMO Capital
-
Scholar Rock (SRRK) PT Raised to $40 at H.C. Wainwright
-
Scholar Rock Holding Corp. (SRRK) Misses Q3 EPS by 8c
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $42 at Piper Sandler
-
Scholar Rock (SRRK) PT Raised to $38 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Prices Upsized 10.27M Share and Warrant Offering at $28.25/sh
-
Scholar Rock (SRRK) PT Raised to $35 at H.C. Wainwright
-
Scholar Rock Holding Corp. (SRRK) call put ratio 1 call to 2.4 puts
-
After-hours movers: PENN Entertainment, Scholar Rock, and more
-
Scholar Rock Holding Corp. (SRRK) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Scholar Rock Holding Corp. (SRRK) Files Mixed Shelf
-
TD Cowen Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $36 at Truist Securities
-
Scholar Rock (SRRK) Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy
-
Scholar Rock Holding Corp. (SRRK) Halted, News Pending
-
Scholar Rock Holding (SRRK) Appoints Beth Shafer to Chief Business Officer
-
Scholar Rock (SRRK) PT Raised to $34 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Misses Q2 EPS by 1c
-
Scholar Rock Holding Corp. (SRRK): New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
-
Scholar Rock (SRRK) PT Raised to $31 at BMO Capital
